2006
DOI: 10.1515/9783110186406.153
|View full text |Cite
|
Sign up to set email alerts
|

Der „kontrollierte individuelle Heilversuch“ als neues Instrument bei der klinischen Erstanwendung risikoreicher Therapieformen – Ethische Analyse einer somatischen Gentherapie für das Wiskott-Aldrich-Syndrom

Abstract: Das Wiskott-Aldrich-Syndrom (WAS), ein genetisch bedingter Immundefekt mit klinischer Manifestation im Kleinkindalter, wird voraussichtlich in näherer Zukunft erstmals versuchsweise durch eine somatische Gentherapie behandelt werden. Im vorliegenden Beitrag werden die wichtigsten medizinisch-naturwissenschaftlichen Fakten dieses Krankheitsbildes sowie die bisherigen Erfahrungen mit somatischen Gentherapien bei anderen Immunmangelsyndromen ausführlich dargestellt. Sodann erfolgt eine ethische Analyse eines mögl… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
4
0
1

Year Published

2006
2006
2023
2023

Publication Types

Select...
4
1
1

Relationship

1
5

Authors

Journals

citations
Cited by 6 publications
(5 citation statements)
references
References 31 publications
0
4
0
1
Order By: Relevance
“…Only standardized documentation and retrospective evaluation would allow us to understand the complete picture of benefits and risks resulting from highly experimental ITAs in Germany. However, other scholars have already suggested the concept of a “controlled ITA”, which includes systematic documentation for risky therapies such as somatic gene therapies [28] or xenotransplantation [29].…”
Section: Discussionmentioning
confidence: 99%
“…Only standardized documentation and retrospective evaluation would allow us to understand the complete picture of benefits and risks resulting from highly experimental ITAs in Germany. However, other scholars have already suggested the concept of a “controlled ITA”, which includes systematic documentation for risky therapies such as somatic gene therapies [28] or xenotransplantation [29].…”
Section: Discussionmentioning
confidence: 99%
“…Solche individuellen Heilversuche werden für die somatische Gentherapie in Anspruch genommen und könnten sich auch für die klinische Nutzung von Ergebnissen der hES-Forschung nahelegen. Es ist jedoch umstritten, ob ein individueller Heilversuch "Forschung" oder primär ärztliches Handeln darstellt [19,20]. Für den Fall, dass in der Bundesrepublik Deutschland einmal beabsichtigt würde, hES-basiert einen individuellen Heilversuch durchzuführen, wäre daher zu klären, inwieweit dies vom Stammzellgesetz abgedeckt wäre.…”
Section: Yes To Research No To Utilization? Medical Pharmacologicalunclassified
“…The famous four principles of biomedical ethics -namely autonomy, beneficence, nonmaleficence and justice [15] -may assist us in sifting through the ethical criteria of relevance to determine whether experimental therapies using viral transduction of genetically modified hematopoietic stem cells with subsequent transplantation into the patient could be indicated [16][17][18]. Self-determination can be built into the working procedure through the requirement for informed consent.…”
Section: Balancing Of Principles and Valuesmentioning
confidence: 99%
“…If one considers the benefit and the hopedfor effectiveness, very young patients will be especially preferable. As a possible solution to the normative stalemate between competing principles of equal merit, a group of authors recently has turned its attention to the rejection of the instrumentalisation of individuals [17]. In the philosophical tradition and in the international debate on human rights this constitutes a core element of the respect for every individual and their dignity.…”
Section: Balancing Of Principles and Valuesmentioning
confidence: 99%
See 1 more Smart Citation